Gilead Sciences Inc.'s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and COVID-19 treatments.
Gilead's third-quarter earnings beat by a wide margin, and biotech raises guidance
Market Watch - 7 Nov 2024 03:22
Gilead Sciences Inc.'s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and COVID-19 treatments.
Share this Article
Recommended